[Vigilanteman]

So, let me get this straight: One worthwhile ingredient actually got slipped into the sh*t sandwich called ObaMaoCare and his bureaucrats are working feverishly to get it out?

[oblomov]

What a clueless article.

There is already a biosimilar on the market in the US, Teva’s Granix, which is a biosimilar of Neupogen, although it was approved through the regular 351(a) pathway.

There are two other products in registration in the 351(k) biosimilar pathway. This means that they are less than 8 months from approval.

[FateAmenableToChange]

But if he lived in Europe, there are more than five versions of that drug available in biosimilar form. These options would have saved him thousands of dollars per year.

I know it's not a perfect answer, but if he spends $800 on a plane ticket to England, gets a concierge doctor, it sounds like he could save a lot and get a european vacation out of it.

[ifinnegan]

Thanks for posting this.

I have been familiar with this part of the bill, which really had nothing to do with Obamacare or anything, but was included along with all sorts of other stuff.

I say this to pointout that this Biosimilar legislation was and is actually good and sensible. Good for business, good for consumers.

I will read this article to see what thenauthor is saying and appreciate your posting it.

[ifinnegan]

This article makes little sense.

But worse than that is it is bereft of factual content.

[DB]

It sounds like to me that if someone doesn’t go to the expense of developing a new drug in the first place, there will be no biosimilar drugs to copy from. The original that cost drastically more to initially produce and get through the regulatory process.

So yes, you can make existing drugs cheaper but at the same time there will be fewer new drugs for other ailments that people suffer from.